EP Patent

EP3693464A2 — Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes

Assigned to Alnylam Pharmaceuticals Inc · Expires 2020-08-12 · 6y expired

What this patent protects

The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.

USPTO Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.

Drugs covered by this patent

Patent Metadata

Patent number
EP3693464A2
Jurisdiction
EP
Classification
—
Expires
2020-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.